Search results
Results from the WOW.Com Content Network
The Toyota HiAce (Japanese: トヨタ・ハイエース, Hepburn: Toyota Haiēsu) (pronounced "High Ace") is a light commercial vehicle produced by the Japanese automobile manufacturer Toyota. First launched in October 1967, the HiAce has since been available in a wide range of body configurations, including a minivan/MPV , minibus , panel van ...
Toyota Granvia / Toyota Hiace SBV (1995–2012) KCH platform (1KZ engine) 1995–present Toyota Granvia; KLH platform (2KD engine) 1995–present Toyota Granvia (Hiace SBV) LXH platform (2L engine) 1995–present Toyota Granvia (Hiace SBV) RCH platform (2RZ engine) 1995–present Toyota Granvia (Hiace SBV) VCH platform (5VZ engine)
The Japanese Toyota Motor Corporation initially acquired 27.8% of the shares in TSAM in 1996, increased this share to 75% in 2002 and finally to 100% in 2009. [1] [3] [4] In 2006, Toyota SA surpassed BMW South Africa as the country's largest automobile exporter. [5] In 2014, Toyota had 8,500 employees in South Africa. [6]
The Toyota Dyna (Japanese: トヨタ・ダイナ) is a light to medium-duty cab over truck for commercial use. In the Japanese market, the Dyna is sold alongside its twin called the Toyoace . The Toyoace was a renaming of the Toyopet SKB Truck as a result of a 1956 public competition with 200,000 entries. [ 7 ] "
The first Toyoace initially sold slowly, due to a price much higher than the three-wheeled trucks with which it was competing. After a large drop in price, however, the ToyoAce went on to change the Japanese market for light trucks in favor of four-wheeled vehicles. [2] There were also panel van, light van, double cab and other body styles ...
The New York City Ballet has been performing "The Nutcracker" for decades. Each year, young dancers make their mark on the ballet.
The SA was Toyota's first new passenger car design (as opposed to updating the AA) after World War II.It was the first in a family of vehicles before the introduction of the Crown.
Doctors and specialists at the Murdoch Children's Research Institute in Melbourne, Australia, are studying and reprogramming the potential of the blood to treat heart failure in children.